Prostate Cancer | Clinical

April 18, 2021

Matthew Smith, MD, PhD, discussed the new hormone therapies entering the treatment landscape for metastatic castration-resistant prostate cancer.

April 10, 2021

According to new research presented during the virtual AACR Annual Meeting 2021, the likelihood of developing metastatic disease or dying of prostate cancer among men with high genetic risk was lowered in men who maintained a healthy lifestyle.

April 07, 2021

Joshi Alumkal, MD assessed the available checkpoint inhibitors for the treatment of mutated metastatic castration-resistant prostate cancer.

April 02, 2021

Alicia K. Morgans, MD, MPH, associate professor of Medicine, Feinberg School of Medicine, Northwestern University, reviewed the clinical trial results for multiple hormonal therapies intended to treat prostate cancer. She explained that many of them show similar outcomes.

April 01, 2021

Arun Azad, MBBS, PhD, discusses ongoing studies of lutetium-177-PSMA radionuclide in patients with prostate cancer.

March 31, 2021

Paul C. Boutros, PhD, MBA, discusses the different challenges facing prostate cancer genetic testing in the academic and community settings.

March 24, 2021

During a virtual Targeted Oncology Case-Based Roundtable event, Eleni Efstathiou, MD, PhD, discussed the case of a 75-year-old patients with metastatic castration-resistant prostate cancer.

March 23, 2021

177Lu-PSMA-617, a targeted radioligand therapy, demonstrated improvement in both progression-free survival and overall survival as treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer compared with best standard of care alone in the phase 3 VISION trial.

March 23, 2021

Tanya B. Dorff, MD, a medical oncologist at the City of Hope Cancer Center, discusses the reasoning behind using PSCA-targeted chimeric antigen receptor T-cell therapy and the design of this early study in an interview with Targeted Oncology.

March 18, 2021

Neeraj Agarwal, MD, discusses the possible adverse events of the randomized phase 3 CONTACT-02 trial of cabozantinib plus atezolizumab versus a second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer.